HomeCompareDASTF vs MRK

DASTF vs MRK: Dividend Comparison 2026

DASTF yields 1.61% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DASTF wins by $3.11M in total portfolio value· pulled ahead in Year 4
10 years
DASTF
DASTF
● Live price
1.61%
Share price
$19.25
Annual div
$0.31
5Y div CAGR
85.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.17M
Annual income
$2,532,050.65
Full DASTF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — DASTF vs MRK

📍 DASTF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDASTFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DASTF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DASTF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DASTF
Annual income on $10K today (after 15% tax)
$136.88/yr
After 10yr DRIP, annual income (after tax)
$2,152,243.05/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, DASTF beats the other by $2,143,646.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DASTF + MRK for your $10,000?

DASTF: 50%MRK: 50%
100% MRK50/50100% DASTF
Portfolio after 10yr
$1.61M
Annual income
$1,271,082.21/yr
Blended yield
78.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

DASTF
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
3.1
Piotroski
7/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DASTF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDASTFMRK
Forward yield1.61%2.81%
Annual dividend / share$0.31$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR85.6%32.7%
Portfolio after 10y$3.17M$57.7K
Annual income after 10y$2,532,050.65$10,113.78
Total dividends collected$3.09M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: DASTF vs MRK ($10,000, DRIP)

YearDASTF PortfolioDASTF Income/yrMRK PortfolioMRK Income/yrGap
1$10,999$298.89$11,213$373.04$214.00MRK
2$12,339$570.23$12,667$512.06$328.00MRK
3$14,312$1,109.63$14,439$708.14$127.00MRK
4← crossover$17,547$2,232.57$16,640$988.16+$907.00DASTF
5$23,523$4,747.72$19,432$1,394.07+$4.1KDASTF
6$36,209$11,040.01$23,057$1,992.90+$13.2KDASTF
7$68,222$29,477.86$27,889$2,894.79+$40.3KDASTF
8$169,334$96,336.87$34,518$4,286.29+$134.8KDASTF
9$595,958$414,770.28$43,912$6,494.35+$552.0KDASTF
10$3,169,726$2,532,050.65$57,714$10,113.78+$3.11MDASTF

DASTF vs MRK: Complete Analysis 2026

DASTFStock

Dassault Systèmes SE provides software solutions and services worldwide. It offers SOLIDWORKS design software for 3D design, electrical and printed circuit board design, product data management, simulation, manufacturing, and technical communication; CATIA, an engineering and design software for product 3D computer-aided design; GEOVIA for modeling and simulating the earth; and BIOVIA that provides the scientific community with advanced biological, chemical, and materials experiences. The company also provides SIMULIA that delivers realistic simulation applications; DELMIA, which enables global industrial operations; 3DVIA that provides 3D space planning solutions; and ENOVIA that enables to plan and track the definition of success for customer. In addition, it offers Centric PLM, a product lifecycle management software solution; 3DEXCITE, a real-time 3D visualization software; NETVIBES, which enables organizations to gather, align, and enrich big data; 3DEXPERIENCE platform that provides organizations a holistic and real-time view of their business activities and ecosystem, as well as connecting people, ideas, data, and solutions together in a single environment; and MEDIDATA, a clinical research study software that provides evidences and insights to pharmaceutical, biotech, medical device, and diagnostic companies, as well as academic researchers. Further, the company provides consulting, deployment, outcome based, and training services. It primarily serves companies in the transportation and mobility; industrial equipment; aerospace and defense; high-tech; life sciences and healthcare; energy and materials; home and lifestyle; construction, cities, and territories; consumer packaged goods and retail; marine and offshore; and business services sectors through distributors and resellers. Dassault Systèmes SE was incorporated in 1981 and is headquartered in Vélizy-Villacoublay, France.

Full DASTF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this DASTF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DASTF vs SCHDDASTF vs JEPIDASTF vs ODASTF vs KODASTF vs MAINDASTF vs JNJDASTF vs ABBVDASTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.